A Second Recall in Fourteen Days
A Houston compounding pharmacy has recalled a lot of injectable glutathione that reached patients in 14 states, and the company says people have already reported getting sick. Optimal Balance Pharmacy announced the voluntary recall on August 19, and the Food and Drug Administration published the company announcement the following day.
The recall is the second in exactly two weeks, involving compounded glutathione injection, pulled for the same reason: pharmacy testing found elevated bacterial endotoxin levels. What changed with this announcement is the geographic footprint and the fact that a different company in a different city experienced the same failure.
According to the company announcement posted by the FDA, Optimal Balance has received reports of adverse events including fever, chills, severe headache, nausea, vomiting, pain, and symptoms consistent with an allergic reaction. The company also stated that injectable products with elevated endotoxin levels carry a reasonable probability of causing significant medical events, including fevers, low blood pressure, inflammatory reactions, anaphylactic shock, and death.
That risk language is the company's own assessment filed with the recall, not an FDA finding of harm in these specific patients. No hospitalizations or deaths have been disclosed in connection with this lot.
Where the Recalled Vials Went
The recall covers one lot of Compounded Glutathione 200 MG/ML in 30 mL multi-dose vials, lot number LG342009076, with an expiration date of October 4, 2026. It is a patient-level recall, meaning the pharmacy is notifying prescribers and patients directly by telephone and mail and arranging for the product's retrieval.
The company states the product was distributed to consumers in Arizona, Colorado, Florida, Illinois, Louisiana, Michigan, New York, Nevada, Oklahoma, Pennsylvania, Texas, Utah, Vermont and Washington. The announcement lists states rather than cities or clinics, so a patient cannot rule out exposure by geography alone within those 14 states.
MedicalDaily previously reported on the Austin pharmacy recall of three glutathione lots announced on August 5. In that action, the Victory Medical Center Pharmacy recall notice disclosed reports of fever, chills, severe headache, nausea, vomiting, tachycardia, changes in blood pressure, body aches, and injection-site reactions. That product was described as going to consumers in Texas, Florida, and New York. The lot numbers, the pharmacy, and the affected states in the newer action are entirely different, so checking a vial against the earlier recall is not sufficient.
A lawsuit filed in Travis County, Texas, in August alleges that a patient was hospitalized after receiving an infusion containing product from one of the recalled Victory Medical lots. Those are untested allegations, and they concern the earlier recall rather than the Houston lot.
Inside an Endotoxin Reaction
Bacterial endotoxin is not a live infection. It is a fragment of the outer membrane of Gram-negative bacteria and can persist in a product even after sterilization has killed the organisms. Because it survives routine sterilization, a vial can be sterile and still be unsafe to inject.
Injected into the bloodstream, endotoxin triggers a rapid inflammatory cascade. Reactions typically begin within minutes to a few hours, not days, which is why the symptom pattern reported by both pharmacies clusters around fever, chills, a racing heartbeat, and blood pressure swings rather than the delayed presentation of an infection.
This failure mode has a documented history in compounded glutathione specifically. In a 2019 compounding alert on dietary ingredient glutathione, the FDA described seven patients at an outpatient clinic who received intravenous L-glutathione and, within minutes of infusion, developed nausea, vomiting, lightheadedness, chills, body aches, and sneezing. One patient developed low blood pressure and difficulty breathing and was transferred to a hospital. FDA laboratory testing found excessive endotoxin in the powder samples, with some results as high as five times the limit the agency calculated for the dose those patients received. The powder had been labeled as a dietary supplement rather than as an ingredient appropriate for sterile injectables.
Glutathione injection is not an FDA-approved drug. It is compounded and marketed off-label for skin brightening, cellular detoxification, and immune support, and its benefits by injection are not well established. Because the product is compounded rather than manufactured under an approved application, no federal agency has reviewed it for safety or effectiveness before it reaches a patient.
Steps for Patients Holding a Vial
Anyone who has recently received a glutathione injection should check the label or ask the clinic for the lot number and compare it with the recall notice, rather than relying on the pharmacy name alone. Patients holding the recalled product should stop using it, quarantine it, and contact the pharmacy to arrange retrieval and a refund. The company line for consumer questions is 218-919-2964, staffed 9 a.m. to 5 p.m. Central Time on weekdays.
People who develop fever, chills, severe headache, vomiting, or symptoms of an allergic reaction after an infusion should contact the prescribing clinician and mention the recall. Sudden difficulty breathing, chest pain, fainting, throat or facial swelling, or a rapid drop in blood pressure warrants emergency evaluation regardless of cause. Reactions can also be reported through the FDA's MedWatch reporting program.
Two recalls in two weeks do not establish a systemic industry failure, and federal regulators have not announced a broader investigation into the supply of compounded glutathione. What is verifiable is that two separate pharmacies found the same contaminant in the same product within two weeks, and that both identified it through their own testing. Patients who use compounded injectables can reasonably ask their provider which pharmacy supplies the product, whether the ingredient is of injectable grade, and whether each batch is endotoxin-tested.
Additional actions may follow. Readers can monitor the FDA recalls and safety alerts index for further postings.
Key Questions Answered
What exactly was recalled? One lot of Optimal Balance Pharmacy Compounded Glutathione 200 MG/ML, 30 mL multi-dose vials, lot LG342009076, expiring October 4, 2026. The company announced the recall on August 19, and the FDA published it on August 20.
Which states received the product? Arizona, Colorado, Florida, Illinois, Louisiana, Michigan, New York, Nevada, Oklahoma, Pennsylvania, Texas, Utah, Vermont, and Washington, according to the company.
Has anyone been hurt? The pharmacy reports adverse events including fever, chills, severe headache, nausea, vomiting, pain, and symptoms consistent with an allergic reaction. No hospitalizations or deaths have been disclosed for this lot.
Is this the same recall MedicalDaily reported earlier this month? No. The earlier action involved a different Austin pharmacy, different lot numbers, and a different distribution list. Checking a vial against only the earlier notice would miss this one.
What is bacterial endotoxin, and why does sterilization not remove it? It is a component of the outer membrane of Gram-negative bacteria that can remain after the bacteria are killed. When injected, it can provoke a rapid immune reaction.
How quickly would symptoms appear? Endotoxin reactions generally begin within minutes to a few hours of an infusion rather than days later.
What should someone do if they still have a vial? Stop using it, set it aside, and contact the pharmacy at 218-919-2964 to arrange a return and refund. Anyone with symptoms should contact their prescribing clinician, and severe symptoms warrant urgent care.
